Is Zoetis Inc. overvalued?

In our latest published analysis dated 2026-10-22, ZTS looks meaningfully undervalued. The price recorded at analysis is 79,6 USD versus our fair value of 95,5 USD; the high endpoint is presented separately as potential value of 131 USD. That implies roughly 19.9% upside to fair value at that date.

What is ZTS's fair value?

Our latest published report, analyzed 2026-10-22, gives ZTS a fair value of 95,5 USD and a potential value of 131 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Zoetis Inc.'s archetype; it is a dated research output, not a live price.

Should I buy ZTS now?

Our latest published rating for ZTS, analyzed 2026-10-22, is Buy. Zoetis Inc. looks meaningfully undervalued at the analysis-date price of 79,6 USD versus fair value of 95,5 USD; potential value is 131 USD. This is research for educational purposes, not personalized investment advice.

What are the biggest risks for ZTS?

The dedicated bear-case section in our report analyzed 2026-10-22 documents Zoetis Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.

What is ZTS's rating?

Our latest published rating for ZTS, analyzed 2026-10-22, is Buy, with a published moat assessment of 8.5/10 (Narrow). It reflects our fair value of 95,5 USD, the potential value of 131 USD, and the price recorded at analysis (79,6 USD).

What archetype is ZTS?

In the latest published report analyzed 2026-10-22, Zoetis Inc. is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ZTS.

ZTS stock analysis | StockMarketAgent.AI

StockMarketAgent researchAnalysé 2026-10-22

Zoetis Inc.

ZTS

Acheter

Hausse potentielle de 19,9 % vers la juste valeur

Report-date price

79,62 $US

Recorded 2026-10-21

Juste valeur

95,48 $US

Valeur potentielle

131,22 $US

Borne haute de valorisation

Avantage concurrentiel

Narrow8.5 / 10

Repli en anglaisFR

Affichage de la source anglaise pendant la traduction

Ce rapport n'a pas encore été traduit. Actualisez dans quelques minutes une fois que la file d'attente de traduction aura rattrapé son retard.

§1 RésuméEN

Réponse en 30 secondesBuy

Prix par rapport à la valeur

Cours: $79.62
Juste valeur: $95.48
Valeur potentielle: $131.22
Au: 2026-10-21

Pourquoi le scénario peut fonctionner

Accelerated international expansion of novel monoclonal antibody pain therapies (Lenivia and Portela) combined with a rich late-stage pipeline of multiple potential blockbuster therapies across kidney disease, oncology, and cardiology.

Ce qui changerait notre avis

Operating margin drops below 34.5% of revenue over a trailing 12-month period.

Zoetis is rated Buy with Fair value of $95.48, offering 19.9% upside from $79.62 (as of 2026-10-21) as market sentiment overreacts to temporary U.S. dermatology competition and clinic visit declines.

The recent sell-off in Zoetis shares followed management's revision of full-year 2026 guidance to revenue of $9.12B to $9.32B (organic contraction of 1% to 3%) and adjusted diluted EPS of $6.15 to $6.25. This reset reflects an 11% decline in Q2 U.S. companion animal sales resulting from lower vet visits and pet owner price sensitivity, alongside targeted gross-to-net discounting to defend dermatology market share.

§2 Cas baissierEN

In a compounding downside event, U.S. veterinary clinic visits remain depressed while competitive alternatives in dermatology capture significant market share against Apoquel and Cytopoint. Management responds with defensive gross-to-net pricing concessions, causing corporate operating margins to compress from 37.84% in FY2025 to 34.5%. Concurrently, U.S. companion animal volume declines persist across FY2027, restricting 5-year top-line growth to 1.5% and reducing annual operating cash flow generation below $2.4B. Under these conditions, multiple expansion fails to materialize and valuation approaches the lower boundary of the fair value range at $71.42.

Bear scenario

Bear

Probability

25%

Return

-10.3%

Path target

$71.42

Revenue compound growth remains constrained by companion animal clinic softness
Operating margin permanently suppressed at 34.5% due to dermatology rebates
Reduced free cash flow curbs share buyback capacity
Persistent softness in U.S. companion animal clinic visits

In the Bear scenario, competitive entrants capture meaningful market share in canine dermatology, forcing permanent gross-to-net rebates that depress operating margins. U.S. veterinary clinic visits remain sluggish, dampening companion animal demand through FY2028 and constraining earnings compound growth.

Comment cette thèse peut échouer

Severe Dermatology Inroads and Permanent Gross-to-Net Degradation

Management acknowledged new competitive entry in U.S. dermatology in Q2 2026 putting volume and market share under pressure and requiring gross-to-net discounting, while revised full-year adjusted net income guidance was cut to a 5% to 9% decline. If competitive entrants capture substantial share in Apoquel and Cytopoint, operating margin drops 300 bps below FY2025 reported levels of 37.84%.^3,5

FV impact

-1.5%

Operating margin 3 points lower throughout

Signaux d'alerte précoce à surveiller

Les cinq évolutions qui affaibliraient notre thèse d’investissement.

U.S. Companion Animal Organic Revenue Growth

Indicates structural volume erosion and clinic visit decline rather than transitory destocking, impairing core companion animal revenue recovery.

Actuel :-11% in Q2 2026

Alerte siSustained organic contraction worse than -5% through FY2027

§3 Avantage concurrentielEN

Narrow

Zoetis possesses a Narrow economic moat anchored by its comprehensive animal health product portfolio, global commercial distribution reach, and deep clinical integration with veterinary practitioners. Animal health therapeutics differ structurally from human pharmaceuticals due to lower patent cliff exposure, smaller brand erosion upon generic entry, and cash-pay consumer dynamics that reward strong brand loyalty and practitioner trust.

The company's commercial scale is unmatched in animal health, generating $9,467M in FY2025 revenue split between U.S. ($5,097M) and International ($4,254M). Although its largest veterinary distributor accounted for approximately 16% of FY2025 revenue, the ultimate purchasing decision rests with thousands of independent clinics and producers who rely on Zoetis technical specialists and point-of-care diagnostic instrumentation.

While competitive entry in dermatology from newer entrants has intensified, requiring targeted gross-to-net pricing investments, the breadth of Zoetis' portfolio across companion animal parasiticides, vaccines, diagnostics, and livestock provides stability that insulates overall corporate returns above capital costs.

Profit économique

Zoetis generated $3,597M in operating income and $2,283M in free cash flow on $9,467M of revenue in FY2025. With a computed WACC of 7.76% and cost of equity of 8.67%, the company produces economic profits substantially in excess of its capital costs.^2,3,6,7

8.5/ 10

Narrow

Sources of advantage

Direct Global Commercial Infrastructure and Distribution ScaleZoetis deploys the industry's largest dedicated animal health technical sales and diagnostics support network, serving veterinarians across more than 100 countries. In FY2025, U.S. operations generated $5,097M and International generated $4,254M, creating commercial scale that independent biotechnology developers cannot easily replicate.Wide
Proprietary Biologics and Monoclonal Antibody Manufacturing MoatZoetis has pioneered category-defining biologic platforms, including Cytopoint for dermatology and Librela/Solensia for osteoarthritis pain, followed by next-generation monoclonal antibodies Lenivia and Portela recently launched in Europe and Canada. Manufacturing complex biologics at global commercial scale creates substantial intellectual property and regulatory barriers.Wide

Menaces connues pour l'avantage
Menace	Gravité	Calendrier	Atténuation
Competitive entry in U.S. canine dermatology targeting Apoquel and Cytopoint market share.	high	Next 12-24 months	Deploying targeted gross-to-net pricing adjustments, leveraging bundled portfolio contracts, and advancing next-generation pipeline assets.⁵

§5 Sensibilité

Taux d’actualisation

Croissance terminale

	2.0%	2.3%	2.5%	2.8%	3.0%
7.7%	$103.97	$106.81	$109.96	$113.50	$117.48
8.2%	$97.25	$99.54	$102.05	$104.83	$107.92
8.7%	$91.56	$93.43	$95.48	$97.71	$100.17
9.2%	$86.66	$88.22	$89.91	$91.74	$93.75
9.7%	$82.39	$83.71	$85.12	$86.65	$88.30

Lignes : taux d’actualisation (Ke pour les bénéfices ; WACC pour les flux de trésorerie). Colonnes : croissance terminale.

Juste valeur

Variation de durée (années)

	-5	-2	0	+2	+5
Juste valeur	93,08 $US	94,30 $US	95,48 $US	96,61 $US	98,24 $US

Durée de l’avantage concurrentiel : 5 ans au point de référence surligné. Les autres hypothèses restent constantes.

Sensitivity reference

The highlighted cell is Fair value when every assumption sits at its base level ($95.48). Each row and column shows what Fair value becomes when one assumption moves.

Falaise des FCF

Free cash flow to the firm stays positive in the first projected year at $2.3B after modeled reinvestment of $409.0M, with terminal value at 81.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.

§7 Arbre de décision sur les résultatsEN

Dépassé

Maintain Buy; Maintain core position sizing and verify whether dermatology gross-to-net pressure is abating.

Déclencheur: Quarterly adjusted diluted EPS exceeding $1.35 and FY2026 revenue tracking toward the top of guidance at $9.32B.⁵

Demonstrates that international growth and operational cost controls are successfully neutralizing domestic dermatology competition and clinic visit declines.

Conforme

Maintain Buy; Maintain scheduled tranche deployment and monitor 2027 initial budget commentary.

Déclencheur: FY2026 adjusted diluted EPS within $6.15 to $6.25 and revenue within $9.12B to $9.32B.⁵

Confirms that management's revised 2026 outlook is realistic and that earnings power remains on track for recovery toward $6.52 per share in FY2027.

Manqué

Downgrade the rating; Halt incremental accumulation and conduct immediate thesis re-assessment regarding moat durability.

Déclencheur: FY2026 adjusted diluted EPS below $6.15 and full-year revenue falling below $9.12B.⁵

Signals that competitor inroads in dermatology are accelerating and clinic traffic is deteriorating further, threatening operating margin support at 34.5%.

Qualité des résultats

Zoetis exhibits high earnings quality supported by strong cash conversion. In FY2025, operating cash flow reached $2,904M and free cash flow was $2,283M, representing an 85.4% conversion rate from reported net income of $2,673M. Stock-based compensation of $83M represents less than 1% of revenue. Non-GAAP adjustments primarily relate to purchase accounting amortization ($90M in FY2026) and discrete restructuring programs ($150M).^6,7

Dynamique des estimations

Following the Q2 2026 earnings release, consensus estimates experienced downward revisions. FY2026 consensus EPS fell from $6.87 pre-event to $6.21, while FY2026 revenue consensus adjusted from $9.74B to $9.25B. FY2027 consensus EPS adjusted from $7.39 to $6.52, reflecting the reset in dermatology pricing assumptions and clinic traffic expectations.¹

Métriques à surveiller avant publication

Métrique:
U.S. Companion Animal Organic Revenue Trend
Actuel-11% reported in Q2 2026
Pourquoi c'est important
Determines whether pet owner price elasticity and veterinary visit contraction are stabilizing.
Métrique:
Dermatology Volume Share and Net Realized Pricing
ActuelDefended via gross-to-net discounting under multi-year contracts
Pourquoi c'est important
Crucial to verify whether Apoquel and Cytopoint retain market leadership against new entrants.

§8 Historique financier

Compte de résultat — six derniers exercices
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$7.78B	$8.08B	$8.54B	$9.26B	$9.47B	+5.0%
Gross profit	$5.31B	$5.48B	$5.83B	$6.40B	$6.67B	+5.9%
Operating income	$2.72B	$2.89B	$3.19B	$3.38B	$3.58B	+7.1%
Net income	$2.04B	$2.11B	$2.34B	$2.49B	$2.67B	+7.0%
EPS (diluted)	$4.27	$4.49	$5.07	$5.47	$6.02	+9.0%
EBITDA	$3.17B	$3.36B	$3.69B	$3.87B	$4.07B	+6.4%
R&D	$508.0M	$539.0M	$614.0M	$686.0M	$698.0M	+8.3%
SG&A	$2.00B	$2.01B	$2.15B	$2.32B	$2.38B	+4.4%

Prévision annuelle retenue
Métrique	2026	2027	2028	2029	2030
Revenue	$9.25B	$9.49B

Flux de trésorerie

Cash generation is exceptionally strong. In FY2025, cash from operations was $2,904M and capex was $621M, yielding free cash flow of $2,283M. Free cash flow conversion stood at 85.4% of reported net income ($2,673M). For FY2026, forecast FCFF of $2,318M remains resilient despite lower revenue, supported by moderate working capital requirements and stable operating tax rates of 20.36%.^2,6,7

Allocation du capital

Zoetis demonstrates disciplined capital allocation focused on organic R&D, capacity investment, and aggressive cash return. In FY2025, was $621M (6.6% of ), supporting next-generation biologics capacity. Capital returns prioritize share repurchases, which reduced diluted to 413.2M by October 2026 from 443.8M diluted average shares in FY2025. Total debt stood at $9,493M as of year-end FY2025, representing a manageable debt-to-capital weight of 21.95%. The board declared a $0.53/share dividend in Q4 2026, maintaining an annualized $2.12 payout.

ROIC

Zoetis generates returns on invested capital well above its cost of capital. With an operating margin of 37.84% in FY2025, a modest reinvestment rate of 15%, and an effective tax rate of 20.36%, economic returns remain stable and insulated from competitive shocks.

ROIC exceeds WACC of 7.76% by over 1,000 basis points.

Operating margins lead the healthcare industry by more than 800 basis points.

FY2025 operating income reached $3,597M on $9,467M revenue (37.84% margin), compared to industry average operating margin of 29.5%.

Dernier chiffre d’affaires9,5 Md $USTCAC du chiffre d’affaires +7,6 %

Marge opérationnelle38,0 %10 périodes fiscales

Dernier flux de trésorerie disponible2,3 Md $USFY2025

Dette nette7,2 Md $USFY2025

Décomposition du compte de résultatComment la taille de l’activité se traduit en bénéfice publié.30 juin 2026

StockMarketAgent.AI

Données de l’historique financier
Chiffre d'affaires	2 468 000 000 $US
Coût des ventes	673 000 000 $US
Marge brute	1 795 000 000 $US
Charges d’exploitation	858 000 000 $US
Résultat d'exploitation	937 000 000 $US
Éléments hors exploitation et impôts	-246 000 000 $US
Résultat net	691 000 000 $US

Aperçu du bilanComment les actifs publiés sont détenus et financés pour la période sélectionnée.

StockMarketAgent.AI

Données de ventilation du bilan
Total de l’actif	15 467 000 000 $US
Trésorerie	2 312 000 000 $US
Actifs courants	6 768 000 000 $US
Total du passif	12 136 000 000 $US
Passifs courants	2 235 000 000 $US
Capitaux propres	3 331 000 000 $US

Passerelle des flux de trésorerieComment le flux de trésorerie d’exploitation est devenu du flux de trésorerie disponible en FY2025.

StockMarketAgent.AI

Rapprochement des flux d’exploitation

Résultat net2,7 Md $USDotations aux amortissements+487 M $USRémunération en actions+83 M $USAutres ajustements opérationnels−339 M $USFlux de trésorerie d'exploitation2,9 Md $US

Rapprochement de la trésorerie d’ouverture à la clôture

Trésorerie d’ouverture2 Md $USFlux de trésorerie d'exploitation+2,9 Md $USFlux d’investissement−748 M $USFlux de financement−1,9 Md $USEffet de change+39 M $USTrésorerie de clôture2,3 Md $US

2,9 Md $US − 621 M $USFlux de trésorerie disponible 2,3 Md $US

Données de la passerelle des flux de trésorerie
Résultat net	2 673 000 000 $US
Entrées d’exploitation	3 243 000 000 $US
Dotations aux amortissements	487 000 000 $US
Rémunération en actions	83 000 000 $US
Flux de trésorerie d'exploitation	2 904 000 000 $US
Sorties d’exploitation	339 000 000 $US
Trésorerie disponible	4 930 000 000 $US
Trésorerie d’ouverture	1 987 000 000 $US
Effet de change	39 000 000 $US
Sorties d’investissement	748 000 000 $US
Capex	621 000 000 $US
Autres activités d’investissement	127 000 000 $US
Sorties de financement	1 870 000 000 $US
Émission nette de dette	2 498 000 000 $US
Rachats d’actions	3 235 000 000 $US
Dividendes versés	889 000 000 $US
Autres activités de financement	244 000 000 $US
Trésorerie de clôture	2 312 000 000 $US
Flux d’investissement	-748 000 000 $US
Flux de financement	-1 870 000 000 $US

Chiffre d’affaires et résultatsComment la taille de l’activité se traduit en bénéfice publié.

Trésorerie et detteLiquidités disponibles face à l’endettement total.

Génération de trésorerieFlux de trésorerie d’exploitation comparé au flux de trésorerie disponible.

RentabilitéÉvolution des marges brute, opérationnelle et nette.

Données financières ponctuelles utilisées dans l’analyse du 2026-10-22.

Données de l’historique financier
Période	Chiffre d'affaires	EBITDA	Résultat net	Flux de trésorerie d'exploitation	Flux de trésorerie disponible	Capex	Dotations aux amortissements	Rémunération en actions	Rachats d’actions	Dividendes versés	Émission nette de dette	Flux d’investissement	Flux de financement	Trésorerie d’ouverture	Trésorerie de clôture	Trésorerie et placements	Dette totale	Marge opérationnelle	ROIC	WACC	Écart ROIC−WACC
2016-12-31	4,9 Md $US	1,6 Md $US	821 M $US	713 M $US	497 M $US	216 M $US	240 M $US	37 M $US	300 M $US	188 M $US	—	-214 M $US	-903 M $US	—	727 M $US	727 M $US	4,5 Md $US	28,7 %	—	5,5 %	—
2017-12-31	5,3 Md $US	1,9 Md $US	864 M $US	1,3 Md $US	1,1 Md $US	224 M $US	242 M $US	44 M $US	500 M $US	206 M $US	—	-270 M $US	-251 M $US	727 M $US	1,6 Md $US	1,6 Md $US	5 Md $US	32,5 %	—	5,4 %	—
2018-12-31	5,8 Md $US	2,2 Md $US	1,4 Md $US	1,8 Md $US	1,5 Md $US	338 M $US	308 M $US	53 M $US	698 M $US	243 M $US	—	-2,3 Md $US	533 M $US	1,6 Md $US	1,6 Md $US	1,7 Md $US	6,5 Md $US	32,3 %	—	5,7 %	—
2019-12-31	6,3 Md $US	2,5 Md $US	1,5 Md $US	1,8 Md $US	1,3 Md $US	460 M $US	412 M $US	67 M $US	626 M $US	314 M $US	—	-504 M $US	-951 M $US	1,6 Md $US	1,9 Md $US	1,9 Md $US	6,6 Md $US	32,2 %	—	5,1 %	—
2020-12-31	6,7 Md $US	2,7 Md $US	1,6 Md $US	2,1 Md $US	1,7 Md $US	453 M $US	441 M $US	59 M $US	250 M $US	380 M $US	—	-572 M $US	123 M $US	1,9 Md $US	3,6 Md $US	3,6 Md $US	7,4 Md $US	34,0 %	—	4,0 %	—
2021-12-31	7,8 Md $US	3,2 Md $US	2 Md $US	2,2 Md $US	1,7 Md $US	477 M $US	448 M $US	58 M $US	743 M $US	474 M $US	—	-458 M $US	-1,9 Md $US	3,6 Md $US	3,5 Md $US	3,5 Md $US	6,7 Md $US	36,0 %	—	4,8 %	—
2022-12-31	8,1 Md $US	3,4 Md $US	2,1 Md $US	1,9 Md $US	1,3 Md $US	586 M $US	465 M $US	62 M $US	1,6 Md $US	611 M $US	1,4 Md $US	-883 M $US	-904 M $US	3,5 Md $US	3,6 Md $US	3,6 Md $US	8,1 Md $US	36,2 %	—	7,3 %	—
2023-12-31	8,5 Md $US	3,7 Md $US	2,3 Md $US	2,4 Md $US	1,6 Md $US	732 M $US	491 M $US	60 M $US	1,1 Md $US	692 M $US	-1,3 Md $US	-777 M $US	-3,1 Md $US	3,6 Md $US	2 Md $US	2 Md $US	6,8 Md $US	35,9 %	—	7,5 %	—
2024-12-31	9,3 Md $US	3,9 Md $US	2,5 Md $US	3 Md $US	2,3 Md $US	655 M $US	497 M $US	74 M $US	1,9 Md $US	786 M $US	-3 M $US	-315 M $US	-2,7 Md $US	2 Md $US	2 Md $US	2 Md $US	6,7 Md $US	36,6 %	—	8,0 %	—
2025-12-31	9,5 Md $US	4,1 Md $US	2,7 Md $US	2,9 Md $US	2,3 Md $US	621 M $US	487 M $US	83 M $US	3,2 Md $US	889 M $US	2,5 Md $US	-748 M $US	-1,9 Md $US	2 Md $US	2,3 Md $US	2,3 Md $US	9,5 Md $US	38,0 %	—	7,4 %	—

§9 Comparaison de valorisation avec les pairs

Zoetis Inc.ZTS

Cours / juste valeur

Juste valeur95,48 $USReport-date price79,62 $US

Date d’évaluation22 oct. 2026

Avantage concurrentielNarrow

Score d’investissement67 / 100

DexCom, Inc.DXCM

Cours / juste valeur

Juste valeur58,97 $USReport-date price85,36 $US

Date d’évaluation04 oct. 2026

Avantage concurrentielWide

Score d’investissement67 / 100

GE HealthCare Technologies Inc.GEHC

Cours / juste valeur

Juste valeur68,29 $USReport-date price64,29 $US

Date d’évaluation05 oct. 2026

Avantage concurrentielNarrow

Score d’investissement62 / 100

Zoetis Inc.ZTS

Cours / juste valeur

Juste valeur95,48 $USReport-date price79,62 $US

Date d’évaluation22 oct. 2026

Avantage concurrentielNarrow

Score d’investissement67 / 100

Multiples des pairs et rentabilité
Symbole	Nom	Cap. boursière	P/E	P/S	EV/EBITDA	ROE

Zoetis Inc. (ZTS) trades at 12.0x forward earnings against a peer median of 16.6x. Its EV/EBITDA of 10.0x compares with a peer median of 14.6x. The comparison uses 4 peers: DexCom Inc., GE HealthCare Technologies Inc., ResMed Inc. and Biogen Inc., as of 2026-10-21.

§10 Secteur et cycleEN

Phase du cycle

Expansion

Industry capex-to-revenue benchmark is 1.1% and industry capex-to-depreciation stands at 0.8x. Zoetis maintains higher capital intensity to support proprietary biologics, investing $621M in capex (6.6% of revenue) in FY2025.⁷

Cycle haussier

The long-term industry expansion is propelled by pet humanization, increasing medicalization rates in emerging markets, preventative veterinary care, and rising global animal protein demand requiring livestock disease prevention.

Cycle baissier

Downside industry conditions stem from pet owner price sensitivity, cumulative veterinary inflation over recent years, and discretionary visit deferrals that pressure volume across companion animal clinics.

Tendances séculaires
Tendance	Impact	Note
Pet Humanization and Premium Veterinary Care	positive	Pet owners increasingly treat pets as family members, prioritizing advanced therapeutics, diagnostics, and monoclonal antibodies regardless of broader economic fluctuations.
Global Protein Demand and Food Security	positive	Rising middle-class populations in emerging markets drive meat and dairy consumption, increasing demand for herd health biosecurity, vaccines, and productivity enhancers.
Cyclical Pet Owner Price Sensitivity and Visit Moderation

Positionnement

Zoetis holds the #1 market share globally in animal health, with leading positions across major companion animal categories (parasiticides, dermatology, pain) and livestock species (cattle, poultry, swine). Its balanced revenue split between the U.S. ($5,097M) and International ($4,254M) insulates the business against localized market downturns.⁸

§11 Gestion de positionEN

Taille de position

4-6%

High conviction is supported by Zoetis' Narrow economic moat, dominant global distribution scale, 85%+ FCF conversion, and a cyclically low valuation of 11.99x forward P/E.³

Risque

Risk management centers on monitoring competitive prescription dynamics in canine dermatology and tracking veterinary clinic visit indicators. Exposure is capped strictly within recommended allocation limits, with downside protection provided by livestock diversification and recurring parasiticide volume.

Tranches d'entrée
Niveau	Action	Pourquoi
$79.62	Initiate primary position tranche	Establishes exposure at a 16.6% discount to Fair value of $95.48.
Below $79.62	Deploy secondary accumulation tranche

Tranches de sortie
Niveau	Action
$95.50 (at Fair value)	Trim initial position tranche
$115.00 (approaching upper fair value band)	Trim secondary position tranche

Points de contrôle trimestriels
Métrique	Seuil	Action
U.S. Companion Animal Revenue Decline	Organic revenue contraction worsening significantly beyond full-year guidance ranges in Q3 or Q4 of FY2026	Re-assess gross-to-net discount trajectory and reduce conviction rating.

ZTS	Zoetis Inc.	$32.9B	12.0x	3.5x	10.0x	64.9%	—
DXCM	DexCom Inc.	$32.4B	27.5x	6.5x	22.7x	38.5%	24.3%
GEHC	GE HealthCare Technologies Inc.	$31.9B	13.0x	1.5x	11.3x	19.4%	15.0%
RMD	ResMed Inc.	$34.5B	18.5x	6.1x	16.6x	24.3%	30.9%
BIIB	Biogen Inc.	$35.6B	14.6x	3.6x	12.7x	4.6%	25.1%

Is Zoetis Inc. overvalued?

What is ZTS's fair value?

Should I buy ZTS now?

What are the biggest risks for ZTS?

What is ZTS's rating?

What archetype is ZTS?

Zoetis Inc.

Names readers of ZTS also follow

Présentation de l’entreprise

U.S. Companion Animal Organic Revenue Growth

Narrow

Sources of advantage

Lenses that set Fair value

Multi-stage Moat Fade

U.S. Companion Animal Organic Revenue Trend

Dermatology Volume Share and Net Realized Pricing

Sources

Corporate Operating EBIT Margin

Full-Year Adjusted Diluted EPS

International Companion Animal Revenue Growth

Free Cash Flow Conversion of Net Income

Forward Earnings

Cash flow DCF

Owner Earnings

Dividend Discount Model

Checks and reference points

Reverse DCF

PEG-adjusted Peer

International Companion Animal Growth Momentum

Livestock Segment Performance and Outbreak Demand

Share Repurchase Execution and Cash Return Pace